Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Conditions
Brief summary
Determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. Recommended phase II dose RP2Ds and schedule of sorafenib and vorinostat defined as the doses and schedule that are the same as or less than the maximum tolerated dose (MTD) and schedule.
Detailed description
This is a phase 1 study of concurrent chemoradiation using a regimen of sorafenib and vorinostat with gemcitabine and radiation following chemotherapy in patients with pancreatic cancer to find the recommended phase II dose (RP2D) of the concurrent chemoradiation combination. A traditional 3+3 dose-escalation design will be conducted for the sorafenib and vorinostat dose escalation. Adenocarcinoma of the pancreas without distant metastasis that has been treated with ≥ 1 prior therapy (not including radiation) encompassing at least 2 months. Adequate hematologic, hepatic, and renal function. Ability to take oral medication. To determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy.This is a dose-escalation trial employing a standard 3+3 schema of sorafenib and vorinostat.
Interventions
DRUGGemcitabine
Given IV
DRUGSorafenib
Given PO
DRUGVorinostat
Given PO
RADIATION3-Dimensional Conformal Radiation Therapy
Undergo 3D CRT
RADIATIONIntensity-Modulated Radiation Therapy
Undergo IMRT
OTHERRosetteSep
Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
OTHERDEPfff
Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
Sponsors
National Cancer Institute (NCI)
Virginia Commonwealth University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adenocarcinoma of the pancreas * Prior therapy with ≥ 1 prior systemic therapy over a period of at least 2 months (eg, at least two 4-week cycles of a regimen such as gemcitabine and nab-paclitaxel; or at least four 2-week cycles of a regimen such as FOLFOX, FOLFIRINOX, or FOLFIRI) -Candidate for additional therapy consisting of radiation with gemcitabine- radiosensitization. * Able to initiate study treatment no later than 9 weeks from last dose of any antineoplastic component of prior therapy regimen. * Recovery from ≥ grade 2 toxicities of prior therapy regimen to grade 1 or baseline, with the exception of anemia and lymphopenia and chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of gemicitabine, sorafenib, and vorinostat (eg, alopecia, changes in pigmentation, stable endocrinopathies). Patients with ≤ grade 2 peripheral sensory or motor neuropathy are eligible.. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<= 3 x upper limit of normal (ULN) for the laboratory * Total bilirubin \<= 1.5 x ULN for the laboratory at the time of enrollment, all forms of biliary stents allowed * Creatinine clearance \>= 45 mL/min as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine and gender * International normalized ratio (INR) \<= 1.5 * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Platelets \>= 100,000/mm\^3 (may not be transfused to meet this level for enrollment) * Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (version \[v\]1.1 * Ability to understand and the willingness to sign a written informed consent document * Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment * Women of childbearing potential and men must agree to use a medically accepted form of birth control during the treatment and for 2 months following completion of study treatment
Exclusion criteria
* Prior radiotherapy for pancreatic cancer * Prior surgical resection of pancreatic cancer * Evidence of metastatic disease * Any investigational agent within 4 weeks of study treatment initiation * Diagnosis or treatment for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy * Intolerance of protocol agents as follows: * Known or presumed intolerance of gemcitabine, vorinostat or sorafenib * Experienced any of the following toxicities with prior gemcitabine adminstration (if given): capillary leak syndrome, posterior reversible encephalopathy, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, unexplained dyspnea or other evidence of severe pulmonary toxicity, or severe hepatic toxicity * Unable to swallow medication * Suspected malabsorption or obstruction; note: use of pancreatic enzyme supplements is allowed to control malabsorption * Contraindication to antiangiogenic agents, including: * Bronchopulmonary hemorrhage/bleeding event \>= grade 2 (Common Terminology Criteria for Adverse Events \[CTCAE\] v4.0) within 12 weeks prior to of treatment * Any other hemorrhage/bleeding event \>= grade 3 (CTCAE v4.0) within 12 weeks prior to initiation of treatment * Serious non-healing wound, ulcer, or bone fracture * Arterial thrombotic or embolic events such as a myocardial infarction or cerebrovascular accident (including transient ischemic attacks) within the 6 months prior to initiation of treatment. Incidental clinically insignificant embolic phenomena that do not require anti-coagulants are not excluded. Also,tumor-associated thrombus of locally-involved vessels does not count as an exclusion criterion. * Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or IV, ventricular arrhythmias requiring anti-arrhythmic therapy, recent (within 6 months) myocardial infarction or unstable coronary artery disease * Concomitant use of other histone deacetylase (HDAC) inhibitors * Planned ongoing administration of STRONG cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers. Examples of clinical inducers and classifications of strong, moderate, and weak interactions are available through the FDA website (Table 3-3 of website): http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm * Persistent heart rate (HR) \< 50 or \> 120 beats per minute (bpm). * QT(c) ≥ 481 ms (\>= grade 2) on electrocardiogram (ECG) prior to initiation of treatment * If baseline QTc on screening ECG meets
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended phase 2 dose and schedule | 18-36 months | Determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor response (complete response or partial response) measured using RECIST version 1.1 | Up to 2 years | Evaluate number of participants with tumor response measured using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. At the completion of concurrent chemoradiation. Tumor response will be measured as complete response, partial response, stable disease, or tumor progression. |
| Surgery | Up to 2 years | Number of participants able to undergo resection after neoadjuvant therapy (chemotherapy followed by concurrent chemoradiation) |
| Number of participants with adverse events using National Cancer Institute CTCAE v4.0 | Up to 30 days following last administration of the chemoradiation treatment | Adverse events using NCI Common Terminology Criteria for Adverse Events, Version 4.0. Adverse events will be listed and summary descriptive statistics will be calculated. |
| Progression-free survival (PFS) | Up to 2 Years | Number of participants with progression free survival (PFS) defined as the percentage of patients able to undergo margin-negative resection following neoadjuvant therapy |
| Overall Survival | Up to 2 Years | The number of participants with overall survival (OS) defined as the time from the date of diagnosis until death by any cause |
| R0 Resection rate | Up to 2 years | Determine the number of patients able to undergo margin-negative resection following neoadjuvant therapy. |
Countries
United States
Outcome results
None listed